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Treatment of the Occlusive Cerebrovascular Disease with 
a Selective Thromboxane Az Synthetase Inhibitor 
SHINICHIRO OKAMOTOヘYASUHIROYONEKAWAll, HAJIME HANDAll, YUTAKA HANDA,1' 
YOSHIHIKO UEMURA1日lcHIROY AN02', MASANORI TOYOSHIMA汽 KENICHIRO1WATSUJI3', 
TETSUAKI TERAURA4', SEN YAMAGATA4', TAKASHI SEK05', HARUMI TsUDA6', 
GnCHIRO UKITA7', Y ASUNORI lNOUE7', YuKIO SH1M1zu8》，andHARUYASU SAWAMl9' 
Department of Neurosurgery, Faculty of Medicine, Kyoto Universityυ，Department of 
Neurosurgery2' and Internal Medicine引， OtowaHospital, Department of N euro-
surgery剖 andInternal Medicine日， KyotoMunicipal Hospital, Department 
of Neurology, The second Kyoto Red Cross Hospital釦， Department
of Neurology, Rakuto Hospital", Department of Neurosurgery, 
Shimizu Hospital8', and Department of Internal Medicine, 
Takeda Hospital町
A newly developed imidazol derivative, OKY-046, which is a selective inhibitor of the 
thromboxane Az synthetase, was administered for over 3 months to 29 patients with transient 
ischemic attack (TIA), reversible ischemic neurological deficit (RIND) or minor stroke. The 
frequency of the ischemic episodes in 14 patients with TIA or RIND (10 TIAs and 4 RINDs, 
respectively) reduced remarkablly after the oral administration of OK Y・046,600 mg a day. Of 14 
Key Words: Transient ischemic attack, Antiplatelet therapy, Platelet aggregation, Occlusive cerebrovascular 
disease, Thromboxane A2 synthetase inhibitor. 
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patients with TIA or RIND, 2 experienced cerebral infarction during the study. The drug had a 
tendency to reduce the ex vz'vo platelet aggregability induced by either arachidonic acid or collagen, 
but not by A DP or epinephrine. There was no adverse effect except for only short-termed mild 
epigastralgia in one patient. 
Although the present study is preliminary, it has appeared from these results that this kind of 
drug is promissing for one of the strategies to treat the patients with TIA and RIND. 
はじめに
Transient ischemic attack (TIA）や reversible



























調査開始前3カ月聞に， TIA, RIND あるいは，
minor strokeの発作のあった患者を対象とした.TIA, 
RINDの定義は，米国 NINCDS特別委員会報告l仰
















られている， aspirin,dipyridamole, sulfinpyrazone, 












































して ADP(1 21. 3 μm), collagen (1. 8 3. 6 μg/ml), 
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高 血 圧 5 3 6 14 
糖尿病 。 2 2 4 
高脂血症 3 。 1 4 
虚血性心疾患 。 1 2 3 
心因原と性な塞る栓心疾の原患 1 。 。 1 
訳 動脈硬化症 。 。 4 4 





































































準誤差は， TIA1.15±0. 26 (0. 50～3. 00), RIND 1. 83 
士0.80 (0. 33～4.00）で，TIAとRINDを合わせると
1. 35±0. 29であった（表3). 
発作時の症状は表4IC示すとおりである．
OKY-046の投与期間は，表51ζ示すとおりで，最
短，最長期間は， TIA1. 5～9カ月， RIND3～4カ














































戸 ?ロunorstroke RIND TIA 
6 1 。5 ～く3カ月
19 13 4 2 3カ月三五～く6カ月
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〔TIA〕 〔RIND〕 〔TIA〕＋〔RIND〕
2 2 2 
町、 +:P<0.10 i: 、園、 m: +:P<0.10 
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＼｜判定時期 l例数｜ 者 「 一 IJbJbI I l効効効効化｜有効以上｜官上
！ ～く3カ月 15 I o 4 o i o I so. o I so. o 
TIA i 3カ月孟～く6カ月 ｜ 5 I o 3 i i o I 60. o I so. a 
16カ月孟～ I 3 I o 3 o o o I loo. o I 10. o 
｜ 終了時 I 10 I o 1 1 2 o I 10. o i so. o 
RIND 13カ月トく6カ月｜ 4円寸 ・o--i:- o I 75.o ¥ 75. a 
｜ ～＜3カ月｜ 2 I o o 2 o o o I loo. o 
minor s帥 e 13カ月壬～く悶｜ 13 1 o s 4 1 o 61.引 92. 3 
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抑 制やや抑制不 変やや冗進冗 進｜一
2 
Collagen 
(1. 8～3. 6 μg/ml) 
3 
Arachidonic acid 
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phenyl）ー2-propenoicacid hydrochloride monhydrate 
は，強力かっ選択的な TXA2合成酵素阻害剤で．
10-•M 以下では cyclooxygenase や PGh 合成酵素
の活性ICは影響しない山.OKY 046は， invirtoお
























































なかった CanadianCooperative Study Gruop3＇の報告
では， aspirin投与群（325mg×4回／日）に，上腹部
痛，胸やけなどの副作用が有意に高率に出現したとさ
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